YOGA FOR CARDIOVASCULAR DISEASE AND REHABILITATION

Integrating Complementary Medicine into Cardiovascular Medicine



Indranill Basu-Ray



Yoga for Cardiovascular Disease and Rehabilitation

Integrating Complementary Medicine into Cardiovascular Medicine

Indranill Basu-Ray

MD (Medicine), DNB (Card), D.Sc. (Yoga Research), FACP, FACC Cardiologist and Interventional Cardiac Electrophysiologist Chairman, American Academy for Yoga in Medicine Director of Clinical Cardiac Electrophysiology Laboratory Director of Cardiovascular Research & Innovations Chairman: Cardio-Pulmonary Resuscitation Committee Lt. Col. Luke Weathers, Jr. VA Medical Center, Memphis, Tennessee, USA 38105 Adjunct Professor; School of Public Health, University of Memphis, Memphis, TN, USA 38152





ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, United Kingdom 525 B Street, Suite 1650, San Diego, CA 92101, United States 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www. elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-323-99645-7

For information on all Academic Press publications visit our website at https://www.elsevier.com/books-and-journals

Publisher: Stacy Masucci Acquisitions Editor: Tracey Lange Editorial Project Manager: Billie Jean Fernandez Production Project Manager: Gomathi Sugumar Cover Designer: Vicky Pearson



Typeset by TNQ Technologies

Dedications

This book is dedicated to the stalwarts who discovered yoga and practiced it to perfection and on whose shoulders we stand today:

> Maharishi Patanjali, Mahavatar Babaji, Adi Shankaracharya, Ramakrishna Paramhansa, Swami Vivekananda, Syamacharan Lahiri Mahasaya, Swami Yukeshwar Giri, Paramhansa Yogananda, Maharishi Aurobindo.

> > And my beloved Guru.

Swami Hariharananda Giri.

I am also thankful to my family.

Late Sankari and Arunangshu Basu-Ray Jayanti and Late Prof. Anil Kumar Ghosh, Ishan and Julie Basu-Ray.

Without their support, gaining knowledge and practicing yoga and medicine together would not be possible.

Contents

XV
xvii
xix
xxi

Section I Epidemiology and pathophysiological mechanisms

1. Introduction to heart disease

Anindya Mukherjee and Indranill Basu-Ray

Introduction	3
Anatomy of the human heart	3
Cardiac embryology	5
Cardiac physiology	5
Cardiac cycle	5
Electrical activity	8
Frank—Starling law	8
Laplace's law	9
Cardiovascular disorders	9
Ischemic heart disease	9
Arrhythmias	14
Heart failure	16
Valvular heart disease	17
Congenital heart disease	19
Pericardial diseases	21
Hypertension	21
Conclusion	22
Clinical guidance	22
Guidelines on prevention and therapy	23
Future recommendations	23
References	25

2. Epidemiology of cardiovascular diseases and yoga as an adjunctive preventative and therapeutic entity

Dorairaj Prabhakaran, Ambalam M. Chandrasekaran and Indranill Basu-Ray

Introduction	
--------------	--

	Epidemiology of CVDs	27
	Causes of cardiovascular death	27
	CVD continuum across lifespan	28
	Public health approaches in managing CVD	
	epidemic	30
	Yoga as an adjunct tool in the management of	
	CVDs	30
	Primary prevention of CVDs through yoga	31
	Secondary prevention of CVDs through	
	yoga	31
	Future recommendations	33
	References	33
3.	Mechanism of yoga in cardiovascular	
	diseases	
	Indranill Basu-Ray and Anindya Mukherjee	
	Introduction	37
	Role of yoga for specific cardiac conditions	37
	Ischemic heart disease	37
	Hypertension	39
	Heart failure	40
	Arrhythmias	40
	Metabolic syndrome	41
	Conclusion	44
	Clinical guidance	44
	Guidelines on prevention and therapy	44
	References	46
4.	Effect of yoga on genes	
	Prity Sahay, Rima Dada and Indranill Basu-Ray	
	Introduction	47
	Key regulators of inflammatory pathways:	
	Neuroendocrine mechanism	47
	Comprehending conserved transcriptional	
	response to adversity during stress	48
	Cellular metabolism with yoga: A mediator to	

a healthy life

Conclusion

References

Further reading

27

Inflammatory biology

Potential pathways connecting yoga:

49

52

54

56

58

5. Cardiovascular epidemiology and need for integrative medicine to fill the gap

Babunageswararao Kanuri and Indranill Basu-Ray

Introduction	59
Epidemiology	59
Historical development	60
Recent advances	61
Yoga as a solution to multiple	
epidemiological risk factors	67
Clinical implications in the field of cardiology	68
Conclusion	70
References	70

6. Neurobiology of yoga

Ganagarajan Inbaraj, Kaviraja Udupa and Indranill Basu-Ray

Introduction	75
Possible neurobiological mechanisms	75
Systematic studies in yoga with neurobiological	
measures	77
Modern neurophysiological research tools	
used in studying the effects of yoga	77
Effects of yoga assessed using ECG and	
heart rate variability	78
Effects of yoga assessed using EEG and	
evoked potentials	78
The effects of yoga on neuroplasticity	79
Yoga and imaging studies	79
Structural/morphological neuroimaging	
studies on yoga	79
Functional neuroimaging studies on yoga	79
Effects of yoga on neural activation	80
Effects of yoga on brain metabolites and	
neurotransmitters	80
Magnetic resonance spectroscopy study	81
Yoga and stress	81
Conclusions and future directions	81
References	82

Section II

Yoga for coronary artery diseases

7. Yoga for primary prevention of coronary heart disease

Anindya Mukherjee and Indranill Basu-Ray

Introduction	87
Epidemiology	88
Role of yoga and meditation	91
Hypertension	91
Diabetes	91
Metabolic syndrome	91

Obesity		99
Smoking cess	ation	99
Psychosocial s	stress	99
Dyslipidemia		102
Inflammation,	oxidative stress, and	
procoagular	nt status	102
Role of yoga i	n management of CVD risk	
score	-	104
Possible mech	anism of action of yoga	
in CHD		105
Conclusion		107
Clinical guida	nce	107
Guidelines on	prevention and therapy	107
References		107
Further readir	ıg	110

8. Yoga for secondary prevention of coronary artery disease

Saurabh Ajit Deshpande and Indranill Basu-Ray Introduction 111 CAD-What does it mean and how common is it? 113 Common risk factors and secondary prevention therapies-An overview 113 Yoga—What does it mean? 114 Early studies evaluating the effects of yoga on the cardiovascular system 115 Nonrandomized studies to evaluate the effect of yoga on secondary prevention of CAD 115 Randomized controlled trials to evaluate the effect of yoga on secondary prevention of CAD 115 Meta-analysis to evaluate the effect of yoga on secondary prevention of CAD 120 Conclusion 122 Our take on yoga in secondary prevention of CAD 122 Further research 122 References 123

Section III Yoga for hypertension

- 9. The role of yoga in the management of essential hypertension
 - Harminder Grewal, Cindy Zhuang and Indranill Basu-Ray

Introduction	127
Definitions	127
Diagnosis	127
Complications	131

Epidemiology	133
Management of hypertension	134
Nonpharmacologic therapy	134
Pharmacologic therapy	135
Yoga as antihypertensive therapy	136
Ethical life choices and personal observances	137
Postures	137
Regulated breathing	137
Withdrawal of the senses, concentration of	
the mind, meditation, and enlightenment	137
Clinical evidence	138
Systematic reviews and meta-analyses	138
Randomized controlled trials	138
Nonrandomized, single-arm, prospective	
trials	139
Cross-sectional study	139
Evidence against yoga as antihypertensive	
therapy	140
Implications for clinical practice	140
References	143

10. Yoga and cardiovascular disease prevention in African American and Hispanic populations

David B. McAdoo, Bettina M. Beech, Keith C. Norris and Indranill Basu-Ray

Introduction	147
Yoga and the African American and Hispanic	
communities	148
Search strategy and selection criteria	149
Overview of the most relevant publications	149
Limitations of yoga trials and cardiovascular	
disease in African American and Hispanic	
study participants	151
Conclusion	154
References	154

Section IV Yoga for metabolic diseases

11. Yoga in prevention of type 2 diabetes mellitus

Vaishali Deshmukh, Ashok Das and Indranill Basu-Ray	
Introduction	159
Epidemiology of prediabetes	161
Assessing risk of diabetes	161
Is T2DM preventable	161
T2DM prevention: Mechanisms involved	162

Prevention of T2DM: Modalities	162
Lifestyle interventions in diabetes	163
Nutritional interventions	163
Physical activity	164
Facilitating behavior change and	
well-being to improve health physical	
activity recommendations	164
Pharmacological interventions	164
Role of yoga and meditation practices in the	<u>)</u>
management of T2DM risk factors	165
Research in yoga and role in T2DM	
prevention	165
ADA guidelines for diabetes prevention	170
Lifestyle behavior change for diabetes	
prevention: Recommendations	170
Pharmacologic intervention	
recommendations	173
Prevention of vascular disease and mortality	/
recommendations	173
Yoga recommendations	173
Discussion	173
References	174

12. Scoping review of yoga as treatment for type 2 DM

Savithri-Chandana Veluri and Indranill Basu-Ray

Introduction	177
Pathogenesis of diabetes	177
Diagnostic tests for T2DM	177
Complications of T2DM	177
Management of T2DM	178
Pharmacological treatment of T2DM	178
Epidemiology	181
China diabetes report 2020–45	182
Role of yoga and meditation in DM type 2	182
Perceptions of yoga as a mind-body	
wellness tool are generally positive	185
Methods	185
Inclusion criteria	185
Exclusion criteria	186
Results	186
Summary of level I evidence of yoga for	
T2DM	186
Conclusion	196
Clinical guidance	196
Guidelines on therapy	198
Precautions and contraindications	199
Limitations and future recommendations	199
Acknowledgments	202
References	202

13. Yoga-based lifestyle as a tool to prevent and manage complications of type 2 diabetes mellitus: Current evidences

Sataz Rahmania, Hemant Bhargav and Indranill Basu-Ray

Introduction	207
Nephropathy	207
Retinopathy	208
Neuropathy	208
Cardiovascular disease	208
Diagnosis of complications	208
Yoga-based lifestyle	208
Role of yoga in diabetes and its associated	
complications: Current evidence	208
Mechanism of action of yoga	210
Tentative yoga-based lifestyle regimen for	
prevention of complications of T2DM	214
Future recommendation	215
Conclusion	215
References	215

14. Yoga in obesity

Sarita Bajaj and Indranill Basu-Ray

217
220
223
223
225
226
227
235
241
242
243
244
244

15. Effects of yoga on metabolic syndrome

Sridip Chatterjee, Palash Pramanik and Indranill Basu-Ray

Introduction	249
History of the metabolic syndrome	249
Standard definition of metabolic syndrome	249
Etiology	250
Prevalence	253

Race/ethnic-specific prevalence	253
Gender-specific prevalence	255
Age-specific prevalence	256
Geographical regions- specific	
prevalence	256
Role of yoga on metabolic risk factors	257
Systematic review and meta-analysis on	
yoga and metabolic syndrome	258
Randomized controlled trials on metabolic	
risk factors and yoga	258
Large multisite randomized controlled trial	
on yoga for metabolic biomarkers	260
Quasi-experimental study on metabolic	
syndrome	260
Case-control study on biological	
parameters of MetS and yoga	261
Other studies on metabolic disorders	261
Yogic approach to the prevention and	
management of better metabolic health	261
Cultivation of right attitudes	262
Yogic diet	262
Yama and niyama	262
Kriyas to cleanse the toxins	263
Surya Namaskara	263
Asana	263
Pranayama	263
Bandhas and mudra	264
Dharana and dhyana	264
Conclusion	264
References	265

Section V

Yoga for arrhythmia and heart failure

16. Yoga in the treatment of heart
failure: A systemic review of all
clinical trials

Ajay Naik and Indranill Basu-Ray

Introduction	269
Epidemiology	269
Role of yoga in management of HF	270
Yoga: Mechanism and clinical benefits	
in CHF	270
Clinical evidence	270
Future studies, outcomes awaited	276
Discussion	276
Implications for clinical practice	277
Conclusion	277
Abbreviations	277
References	278

17. Yoga and cardiac autonomic nervous system

Indranill Basu-Ray and Jayasree Pillarisetti

Introduction	279
Cardiac autonomic nervous system	279
Cardiac neuroanatomy	279
Yoga and HRV	281
Pranayama	283
Yoga and syncope	283
Yoga and ventricular arrhythmias	286
Future recommendations	288
Conclusion	288
References	288

18. Yoga and atrial fibrillation

Jayasree Pillarisetti and Indranill Basu-Ray

Introduction	291
Epidemiology	
AF epidemiology	291
AF pathogenesis	291
Role of ANS in AF	
Obstructive sleep apnea	293
Diabetes	294
Alcohol	295
Smoking	295
Exercise and physical inactivity	296
Yoga in AF	
Clinical evidence and future directions	300
Conclusion	301
References	301

Section VI Yoga for stroke and dementia

19. Role of yoga in stroke: Prevention, management, and rehabilitation

Pawan Ojha, Arjun G. Shah and Indranill Basu-Ray

Introduction	305
Epidemiology of stroke	305
Economic burden of stroke	306
Etiology of stroke: risk factors	307
Management of stroke	309
Poststroke complications	310
Poststroke spasticity	310
Motor weakness	310
Balancing	310
Gait	310
Cognitive and behavorial	310
Yoga in the context of stroke	312
Yoga: possible mechanisms	312
Yoga in stroke rehabilitation: evidence	312

Psychological well-being after stroke	313
Quality of life	314
Balancing	314
Gait	315
Motor weakness and stiffness	315
Yoga in prevention of stroke: addressing	
vascular risk factors	315
Barriers to the practice of yoga	315
Conclusion	316
Clinical guidance	316
Guidelines	316
Recommendations	316
References	316

20. Role of yoga in vascular dementia and other dementia conditions of the elderly

Shripad Pujari and Indranill Basu-Ray

Introduction	319
Basic mechanisms by which yoga causes	
changes in mental health	319
Effect of yoga on oxidative stress	320
Effect on brain-derived neurotrophic factor	
(BDNF)	320
Effect on angiogenin and VEGF	320
Effect of yoga on cytokines	321
Effect of yoga on neuro-transmitters	322
Effect on hormones (melatonin, cortisol, and	
beta-endorphin)	323
Effects at genetic level	324
At autonomic function level	324
Effect on brain oxygenation	325
Effect on regional cerebral blood	
flow (rCBF)	325
Investigative tools measuring changes	
in brain related to cognition and impact	
of yoga on them	326
Electroencephalogram	326
Electrophysiology: P300 evoked potentials	326
Magnetic resonance imaging	327
PET and SPECT	328
Clinical evidence studying the impact of	
yoga on cognition in different categories	
of people	328
Impact of yoga on cognition in normal	
healthy individuals	330
Yoga to prevent the development of	
dementia	330
Impact of yoga on those with risk factors	
for cerebrovascular disease (which is the	
cause of vascular dementia)	330
Conclusion	331
Clinical guidance	331
Guidelines on prevention and therapy	331
References	332

Section VII Yoga for miscellaneous cardiovascular risks

21. Chronic inflammatory arthritis, cardiovascular risk and potential role of yoga-based lifestyle intervention

Praerna Chowdhury, Sataz Rahmania, Hemant Bhargav and Indranill Basu-Ray

Introduction	337
Clinical characteristics	337
CIA and cardiovascular disease connection	338
Etiological factors responsible for	
increased CV risk in CIA and	
pathogenesis	339
Pathophysiology	339
Specific factors	339
Diagnosis	341
Standard treatment	342
Prognosis	342
Yoga and CIA	342
Epidemiology of CVD in CIA	342
Role of yoga in CVD risk in CIA	343
Conclusion	344
Clinical guidance	344
Future recommendation	347
References	347

22. Yoga for depression as a risk factor for cardiovascular disease

Preethi Veerappa Reddy and Indranill Basu-Ray

Introduction	353
Risk factors for depression in CVD	354
Course of depression in CVD	354
Depression and cardiac outcomes	354
Mechanisms linking depression and cardiac	
disease	355
Yoga and how it works	357
Effects on neurochemistry	357
Effects on inflammatory pathways	357
Effects on oxidative stress markers	357
Effects on neurophysiology	358
Effects on brain structure and function	358
Evidence for yoga in depression and	
cardiovascular disease	358
Yoga for depression	358
Yoga for cardiovascular disease	359
Conclusion	361
Guidelines for Yoga Therapy	362
Scope for future research	362
References	362

23. Addressing cardiovascular disease risk through yoga: a focus on anxiety and psychosomatic stress reduction

Nishitha Jasti, Bharath Holla and Indranill Basu-Ray Introduction

Stress and cardiovascular diseases	367
Anxiety and cardiovascular diseases	371
Yoga as a buffer for stress and anxiety	373
Role of yoga in reducing stress, anxiety,	
and risk of cardiovascular diseases	373
Review of meta-analysis and systematic	
review	373
Randomized controlled trials: Stress/anxiety	
and cardiovascular disorders	376
Single-arm prepost design	376
Conclusion	381
Clinical insights: Tentative yoga module for	
comorbid anxiety/stress and cardiovascular	
diseases	381
Guidelines on prevention and therapy	382
Future recommendations	382
References	383

367

Section VIII Yogic diet-based therapy

24. Diet therapy and lifestyle based on yoga for diabetes mellitus

Harish R. Joshi, Nidhi H. Joshi and Indranill Basu-Ray

Introduction	389
Epidemiology of diabetes and lifestyle	
disorders	390
Research on the role of yoga in diabetes	
mellitus	390
Dietary approaches in yoga	393
Apathya Ahara (contraindicated food items)	
for diabetes are	393
Yogic diet and lifestyle protocols for diabetes	393
Pathya (allowed food items) Ahara for	
diabetics	394
Recommended Pathya Ahara for diabetics	394
Role of fruits, vegetables, spices, and	
seeds in diabetes	395
Conventional approach to diet therapy	
based on yoga and ayurveda	395
Other lifestyle-related issues to consider	396
Pathya Vihara for diabetics in ayurveda/yoga	
schools	396
Contemporary scientific supporting data	396

Need of awareness of yoga as well as	
traditional, thought process in managing	
health	397
Yoga and behavioral aspects of eating	398
Yoga and eating disorders	399
Conclusion	399
References	400

25. Diet therapy for dyslipidemia: A review of clinical trials

Alka Mohan Chutani, Anjani Bakshi and Indranill Basu-Ray

Introduction	403
Epidemiology	403
India and South Asia	404
Management of dyslipidemia for CVD risk	
prevention	405
Clinical evidence	407
Systematic review and meta-analysis	408
Other nutrients	410
Randomized controlled/crossover trials	410
Fruits, vegetables, and plant-based diets	412
Functional foods	412
Case-control or cohort study	412
Dietary pattern and dietary habits	412
Cross-sectional study	413
Discussion	413
Therapeutic lifestyle changes in	
LDL-lowering therapy	415
Implications for clinical practice	415
Implications for future research	416
References	418

26. Plant-based diet and cardiovascular health

Koushik R. Reddy and Indranill Basu Ray

Introduction Definition of plant-based diets Potential mechanisms	421 421 422
Macronutrient components of diet and	
cardiovascular disease	422
Dietary fats	422
Dietary carbohydrates	422
Dietary proteins	422
Dietary patterns	423
Plant based diets: Cardiovascular risk factors	423
Hypertension	423
Diabetes	423
Obesity	424
Blood lipids	425
-	

Gut microbiome	425
Inflammatory markers	426
Endothelial function	426
Plant-based diets: Ischemic heart disease	427
Plant-based diets: Heart failure	428
Plant-based diets: Stroke	429
Plant-based diets: Cardiovascular and	
all-cause mortality	429
Healthy vs. unhealthy plant-based diet	430
Conclusion	430
References	430

Section IX

Yoga for cardiovascular rehabilitation

27. Cardiac rehabilitation and yoga

Alice Fann and Indranill Basu-Ray

Introduction	437
Cardiac rehabilitation	437
Phases of cardiac rehabilitation	438
Epidemiology	439
Outcomes of cardiac rehabilitation	439
Assessment of use of cardiac rehabilitation	
guidelines	440
Global use of cardiac rehabilitation	440
Yoga and cardiac rehabilitation research	442
Yoga-CaRe trials	442
Other trials including yoga with cardiac	
rehabilitation	442
Cardiac rehabilitation with yoga—effects	
on quality of life	443
Cardiac rehabilitation and	
yoga—neuroendocrine effects	443
Cardiac rehabilitation and	
yoga—acceptability	444
Review of cardiac rehabilitation and yoga	444
Components of yoga-based cardiac	
rehabilitation	445
Conclusion	448
References	449

28. Role of yoga in postcardiac surgery rehabilitation

Nirmal Kumar Gupta, Reetobaan Datta and Indranill Basu-Ray

Introduction	451
What is cardiac rehabilitation (CR)	451
Epidemiology	453

The number-1 killer in the modern era	454
Modern reductionist approach in	
medicine: Historical perspective	454
Why the world needs a newer holistic	
approach	455
Inflammatory basis of CVD: Possible role	
of yoga including meditation	455
An alternative holistic approach—Yoga,	
including meditation	456
Recommended yoga based post cardiac	
surgery protocol	457
Conclusion: Lessons drawn	458
References	459

29. The role of yoga in palliative care settings

Reetobaan Datta and Indranill Basu-Ray

Introduction	463
Definition and epidemiology	463
Reasons for adopting complementary	
therapies	463
Efficacy of complementary therapies in	
palliative care	466
Rationale for adopting yoga as a therapy	
in palliative care	466
Current role of yoga in palliative care	
settings	468
Future directions	471
Conclusions	471
Clinical guidance	471
References	471

Section X Yoga for special populations

30. Yoga for addiction management

Sridip Chatterjee, Puneet Bhattacharya and Indranill Basu-Ray

Introduction	
History and science of the drug addiction	
cycle	

Epidemiology	479
Role of yoga in addiction	481
Mechanism of addiction and role of yoga	
at the neurophysiological level	482
Yoga and the nervous system	482
Yoga and nicotine-use disorders	484
Yoga and alcohol-use disorders	485
Yoga and opioids-use disorders	485
Yoga and cocaine-use disorders	486
Conclusion	486
References	486
Further reading	488

31. Role of yoga in cardiovascular disease prevention in the Indian population

Pawan Suri, Neelu Khanna and Indranill Basu Ray

Introduction	489
Burden of CVD and its risk factors in India	491
Smoking	492
Dietary habits	492
Physical activity	492
Hypertension	492
Diabetes	492
Dyslipidemia	493
Obesity	493
Cardiovascular disease prevention	493
Physiological effects of yoga	493
Clinical evidence	494
Nonrandomized controlled trials	495
The single-group studies	495
The one-time studies	495
Randomized controlled trials	495
Yoga in primary prevention	495
Yoga in secondary prevention	496
Reduction in MACE	501
Discussion	501
Conclusion	503
References	503

477 Index

477

507

Contributors

- Ajay Naik, Arrhythmia and Heart Failure Device Division, Marengo CIMS Hospital, Ahmedabad, Gujarat, India
- Alice Fann, Atlanta Veterans Affairs Medical Center, Atlanta, GA, United States
- Alka Mohan Chutani, Department of Food & Nutrition and Food Technology, Lady Irwin College, University of Delhi, New Delhi, India; Department of Dietetics, All India Institute of Medical Sciences (AIIMS), New Delhi, India
- Ambalam M. Chandrasekaran, Centre for Chronic Disease Control, New Delhi, India
- Anindya Mukherjee, Cardiology, Bristol Heart Institute, Bristol, United Kingdom; Adult Congenital Heart Disease, Bristol Heart Institute, Bristol, United Kingdom
- Anjani Bakshi, Department of Food & Nutrition and Food Technology, Lady Irwin College, University of Delhi, New Delhi, India
- Arjun G. Shah, JJ Hospital and Grant Govt. Medical College, Mumbai, Maharashtra, India
- Ashok Das, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji Vidyapeeth (SBV), Puducherry, India
- Babunageswararao Kanuri, Division of Cardiac Surgery, Ohio State University Wexner Medical Center, Columbus, OH, United States
- Bettina M. Beech, University of Houston, Houston, TX, United States
- Bharath Holla, Department of Integrative Medicine, NIMHANS, Bengaluru, Karnataka, India
- **Cindy Zhuang**, School of Medicine, SUNY Upstate Medical University, Syracuse, NY, United States
- **David B. McAdoo**, Howard University, Washington, DC, United States

- Dorairaj Prabhakaran, Centre for Chronic Disease Control, New Delhi, India
- Ganagarajan Inbaraj, Department of Neurophysiology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India
- Harish R. Joshi, DNB Consultant Endocrinologist, Endocrine and diabetes care center, Hubbali, Karnataka, India
- Harminder Grewal, Department of Family Medicine, Boonshoft School of Medicine, Wright State University, Dayton, OH, United States
- Hemant Bhargav, Department of Integrative Medicine, NIMHANS, Bengaluru, Karnataka, India
- Indranill Basu-Ray, MD (Medicine), DNB (Card), D.Sc. (Yoga Research), FACP, FACC; Cardiologist and Interventional Cardiac Electrophysiologist; Chairman, American Academy for Yoga in Medicine; Director of Clinical Cardiac Electrophysiology Laboratory; Director of Cardiovascular Research & Innovations; Chairman: Cardio-Pulmonary Resuscitation Committee; Lt. Col. Luke Weathers, Jr. VA Medical Center, Memphis, Tennessee, USA 38105; Adjunct Professor; School of Public Health, University of Memphis, Memphis, TN, USA 38152
- Jayasree Pillarisetti, UT Health San Antonio, Long School of Medicine, San Antonio, TX, United States
- Kaviraja Udupa, Department of Neurophysiology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India
- Keith C. Norris, UCLA, Los Angeles, CA, United States
- Koushik R. Reddy, Interventional Cardiology, James a. Haley VA Medical Center, Tampa, FL, United States; University of South Florida, Division of Cardiology, Tampa, FL, United States
- Neelu Khanna, Global MultiSpeciality Hospital, Jalandhar, Punjab, India

- Nidhi H. Joshi, D Y Patil medical college, Kolhapur, Maharashtra, India
- Nirmal Kumar Gupta, Department of Cardiovascular and Thoracic Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; Centre of Integrative Medicine and Research, SGPGIMS, Lucknow, Uttar Pradesh, India
- Nishitha Jasti, Department of Integrative Medicine, NIMHANS, Bengaluru, Karnataka, India
- Palash Pramanik, Department of Physical Education, Jadavpur University, Kolkata, West Bengal, India
- Pawan Ojha, JJ Hospital and Grant Govt. Medical College, Mumbai, Maharashtra, India
- Pawan Suri, Global MultiSpeciality Hospital, Jalandhar, Punjab, India
- Praerna Chowdhury, Center for Consciousness Studies, Department of Neurophysiology, NIMHANS, Bengaluru, Karnataka, India
- Preethi Veerappa Reddy, Department of Psychiatry, NIMHANS, Bengaluru, Karnataka, India
- Prity Sahay, Department of Anatomy, All India Institute of Medical Sciences, New Delhi, Delhi, India
- **Puneet Bhattacharya**, Department of Physical Education, Jadavpur University, Kolkata, West Bengal, India

- Reetobaan Datta, PGY-1 Medicine-Pediatrics Resident, Tulane University School of Medicine, New Orleans, LA, United States
- Rima Dada, Lab for Molecular Reproduction and Genetics, Deptartment Anatomy, AIIMS, New Delhi, Delhi, India
- Sarita Bajaj, Department of Medicine, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India
- Sataz Rahmania, Department of Integrative Medicine, NIMHANS, Bengaluru, Karnataka, India
- Saurabh Ajit Deshpande, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
- Savithri-Chandana Veluri, Family Medicine Women's Health Veteran's Administration, Orlando, FL, United States
- Shripad Pujari, Noble Hospital & Research Center, Pune, Maharashtra, India
- Sridip Chatterjee, Department of Physical Education, Jadavpur University, Kolkata, West Bengal, India
- Vaishali Deshmukh, Department Deenanath Mangeshkar Hospital & Research Centre, Deshmukh Clinic & Research Centre, Pune, Maharashtra, India

Foreword

Cardiovascular disease remains the largest pandemic, killing both men and women throughout the world. One person dies every 33 s in the United States from cardiovascular disease. About 695,000 people in the United States died from heart disease in 2021—that is one in every five deaths. Cardiovascular disease costs consume an astronomical number of financial resources, including about \$239.9 billion annually. While the incidence of cardiovascular disease has plateaued in developed nations, it continues to rise in middle- and low-income countries.

It does not have to be this way.

Inflammation is one of the biological mechanisms that cause cardiovascular disease. There is some evidence that multiple traditional cardiac risk factors, including hypertension, diabetes mellitus, and hyperlipidemia, are all associated with inflammation.

Psychological stress is now considered an independent risk factor for cardiovascular disease. Excessive stress can both initiate and perpetuate cardiovascular disease. Emotional stress induces genetic and endocrinal changes that perpetuate inflammation in blood vessels, leading to heart attack, stroke, or peripheral arterial disease. Furthermore, stress also amplifies sympathetic discharge and attenuates parasympathetic discharge, and this imbalance may cause arrhythmias.

Chronic stress is toxic, generating a cascade of inflammatory cytokines that decrease immunity and generate vascular inflammation. Over time, everyday stresses such as being stuck in traffic, financial pressures, and relationship issues may contribute to chronic inflammation and cardiovascular disease.

Fortunately, stress comes not just from what we do; more important is how we *react* to what we do. By practicing stress management techniques such as yoga and meditation on a regular basis, even a few minutes a day, we can buffer the harmful effects of stress. As a patient once shared with me, "I used to have a short fuse and would explode easily. Now, my fuse is longer. Even if the situation hasn't changed, *I* have."

My colleagues and I conducted randomized controlled trials documenting, for the first time, that a lifestyle medicine intervention including a whole foods plant-based diet low in fat, sugar, and refined carbohydrates, moderate exercise, stress management (including yoga), and social support can often reverse the progression of even severe coronary heart disease, without drugs or surgery.

Over the last few decades, scientific evidence of the many beneficial effects of yoga has been found through genetic, epigenetic, molecular, and cellular studies. While yoga as a series of postures has become popular worldwide, it is important to remember that although all these postures are useful, yoga is much more than a handful of physical exercises. It is, in fact, a cumulative practice of physical exercise, specialized breathing techniques, and mindfulness meditation. It quiets down the mind and body, enabling us to experience an inner sense of peace and well-being that is always there if we just stop disturbing it.

This book presents the clinical and research evidence of yoga's role in cardiovascular diseases as a preventive and therapeutic strategy. It combines decades of research that enables physicians to use yoga as a clinical methodology to treat and prevent many diseases. It also highlights the existing research on the power of yoga and outlines future research strategies to better understand yoga's role. Yoga is freely available, requiring no costly equipment or technology. Patience and practice are the only requirements.

Dr. Indranill Basu-Ray is an eminent Cardiologist and a Cardiac Electrophysiologist at the forefront of yoga research today. He is one of the authors of the American Heart Association's statement on using meditation for cardiovascular risk reduction. He has been practicing yoga, including deep meditation, since age six. Trained by various Himalayan masters, he has been a practitioner of Kriya Yoga. He was initiated into Kriya Yoga by Swami Hariharananda Giri, the brother disciple of Paramhansa Yogananda who wrote the classic book, *Autobiography of a Yogi*.

Dr. Basu-Ray's book is a combined effort of around 40 eminent researchers and clinicians. Every chapter has been compiled with the latest updates included. Thus, this book is a storehouse of information on clinical yoga therapy for clinicians and researchers. Also, every chapter is clinically oriented for healthcare professionals to use in daily clinical

practice. It details the yogic postures used in clinical trials for many different diseases and provides guidelines on prevention and therapeutic use. It also provides recommendations for future research topics that can help move the science of yoga forward.

I commend Dr. Basu-Ray and the coauthors for compiling such a monumental book that brings to light the research on yoga to enable its clinical use. This endeavor will inspire many clinicians to practice yoga therapy as a cost-effective and medically effective modality to treat and prevent cardiovascular diseases.

Dean Ornish, MD

Founder and President, Preventive Medicine Research Institute Clinical Professor of Medicine, University of California, San Francisco

Preface

After spending over two decades learning, teaching, and mentoring residents and fellows in Medicine and Cardiology, I was always intrigued by the epidemic explosion of cardiovascular disorders worldwide. As medical students, we had patients admitted with heart attacks, predominantly in their 50s and 60s. Contrarily, today, we find that no age is a bar. We have had multiple patients with clinically significant coronary artery disease, even in their 30s. This spurred my interest to go beyond clinical medicine and understand the cause and remedy for such an epidemic. It is undeniable that medicine has made tremendous strides not only in unraveling the pathophysiology of diseases but also in management, with technological advancement occurring almost every day. Despite this, there has been no respite in the evolving heart disease numbers.

I have been a practitioner of Kriya yoga for over three decades now. This robust protocol includes physical exercise, modulated breathing, mindfulness, and meditation. My yoga mentor, Swami Hariharananda Giri, a monk of the Kriya Yoga clan, wanted me to become a cardiologist, understand and explain the mechanism of yoga action scientifically, and spread it to the ordinary person to ensure health and well-being. "Yoga is a potent mechanism to achieve every goal in life, certainly health," he contended. "However, it needs to be understood and spread scientifically." My graduation to be a cardiologist was long and arduous as I had to repeat my training in the United States after being initially trained in India. However, this extended association with learning and research in some of the topmost institutions in the world espoused me to think about the possible reason why even low- and middle-income countries (LMICs) of the world seem to be having a deluge of coronary artery disease. In the United States, nearly one in three (~ 80 million) adults have cardiovascular disease (CVD), which imparts a heavy economic burden, including estimated direct costs of approximately \$500 billion. It has been projected that by 2035, nearly half of the U.S. population will have some form of cardiovascular disease. Even nations with a younger population, like India, have an explosion of cardiovascular disease in a malignant form that affects much younger population with more severe disease.

My experience and understanding of yoga's essence helped me find an answer. The basic tenets of yoga say that the mind and body are like one entity—they keep each other informed at every second of our existence. Thus, an aberrant mental state garnered by diurnal experience in a world of stress and competitiveness evokes a "flight and fight" reaction, activating genes, hormones, and pathophysiological changes that induce heart diseases. Aberrant lifestyle added to the increased stress of existence as is ostensible today have clubbed together to create a dangerous cascade of heart attacks, heart failure, arrhythmia, and death. Almost half the planet's population suffers from hypertension, a harbinger of other dangerous cardiac diseases. Thus, the cure is only possible if we quieten the mind and douse the inflammatory fire within the body by extinguishing the initial flame initiated inside our brains.

The scientific interrogation of yoga started relatively late in the West but was a welcome change. Funding of such research by the National Institute of Health and the rising popularity of yoga are some of the reasons for this. Many researchers started studying yoga's clinical effects in the last few decades. Numerous leading oncology institutions started implementing yoga protocols as part of their treatment strategies. It is fair to state that oncology led the way to implement yogic therapy in medicine.

Cardiovascular disease remains the largest killer on this planet, killing twice the number of people than cancer. There is robust evidence that multiple cardiac risk factors, including hypertension, diabetes mellitus, and hyperlipidemia, benefit from yoga, including meditation. Stress is now considered the predominant underlying cause of CVD, responsible for the overwhelming majority of mortality on earth. Accumulated evidence in the last decade points to the stress-mediated genetic, epigenetic, and endocrinal changes perpetuating inflammation in blood vessels, leading to heart attack, stroke, or peripheral arterial disease. Yoga has been shown to attenuate many such pathological entities through stress reduction. Aging is a risk factor for aberrant pathophysiological changes leading to increased risk of coronary artery disease and arrhythmias. There is some initial evidence that yoga may help reduce cellular aging. Moreover, it is now established that organ aging, particularly that of the brain, can be decreased by sustained yoga practice. Meditation has been shown to help

the growth of different regions of the cerebral cortex, which now remains firmly substantiated through multiple imaging studies among different cohorts of volunteers. CVD imparts a heavy economic burden on our healthcare system. The CVD costs of care continue to rise, with the current expenses for treatment accounting for nearly \$1 of every \$6 spent on healthcare. Yoga can help lower this cost through its proven effectiveness in primordial, primary, and secondary prevention.

Yoga for Cardiovascular Disease and Rehabilitation: Integrating Complementary Medicine into Cardiovascular Medicine elaborates recent research, clinical trials, and experiments on yoga and meditation as a preventative measure and treatment for various major cardiovascular diseases, including hypertension, hyperlipidemia, coronary artery disease, and metabolic syndromes. It also discusses the current knowledge of yoga's role in ameliorating cardiac dysfunction initiated by emotion and other factors that create and perpetuate vascular inflammation. Cellular, genetic, and molecular effects of yoga based on experimental evidence are also covered in detail, providing readers with the latest research on the impact of yoga and meditation on heart disease. This book also explores current knowledge gaps in yoga research to facilitate further research. It is a comprehensive reference to physicians, scientists, and clinicians interested in understanding yoga's role in preventing and treating cardiovascular diseases. This book adopts a translational approach, exploring yoga's clinical, cellular, genetic, and molecular effects on health based on the latest research evidence.

This book would never have seen the light of day without the belief and support of my acquisition editor, Stacy Masucci, who believed in me and the power of yoga as a potent healing entity. I also remain thankful to the Elsevier team, including Ana Garcia and Tracy Lange, for contributing to this project. I remain immensely grateful to Ms. Kristi Anderson and Ms. Billie Jean Fernandez, my editorial project managers, whose astute working ethics and friendly ambiance helped me throughout the long and arduous process of writing the book. I am grateful to all the authors who collaborated with me to create this unique work. Most of them are busy clinicians and researchers with extensive experience in both clinical medicine and yoga. I am also thankful to my postdoctorate research scholars, led by Dr. Sukhendu Mandal, Dr. Inbaraj G and Dr. Manjot Singh, and my doctoral research volunteer, Ms. Khusboo Arya, and my graduate research scholars, led by Reetoban Dutta, including Oishi Roy Choudhury, Nandita Bhalla, Nemalidinne Krishna Vani, Abinay Siva Kumar Reddy, and Mridul Sarangal, without whose dedication and hard work it would have been impossible for me to complete this substantial undertaking.

I am finally thankful to my wife Julie and my son Ishan, who had to put up with my being busy with this project evening after evening for over a year that I could have spent with them. Without their substantial help and sacrifice, this project would have never seen completion.

> Indranill Basu-Ray Memphis, TN, United States

Abbreviations

18F-FDG	18F-fluorodeoxyglucose
5HT	5-hydroxytryptamine
AA	African American
AACE	American Association of Clinical Endocrinologists
AACPR	American Association of Cardiovascular and Pulmonary Rehabilitation
AADs	Antiarrhythmic Drugs
ABPM	Ambulatory Blood Pressure Monitoring
ACC	American College of Cardiology
ACC/AHA	American College of Cardiology/American Heart Association
ACCF	American College of Cardiology Foundation
ACE	Angiotensin-Converting Enzyme
ACEI	Angiotensin Converting Enzyme Inhibitor
ACPA	Anti-Citrullinated Protein Antibody
ACS	Acute Coronary Syndrome
ACTH	Adrenocorticotrophic Hormone
AD	Alzheimer's Disease
ADA	American Diabetes Association
ADAS	Alzheimer's Disease Assessment Scale
ADM	Adrenomedullin
ADMA	Asymmetric Dimethylarginine
AEs	Adverse Events
AEBs	Abnormal Eating Behaviors
AF	Atrial Fibrillation
AFR	Africa Region
AG	Acylated Ghrelin
AGB	Adjustable Gastric Band
AGi	Alpha-Glucosidase Inhibitor
АНА	American Heart Association
AHD	Atherosclerotic Heart Disease
AI	Aortic Insufficiency
AIR	Acute phase Insulin Release
AMI	Acute Myocardial Infarction
AMPK	AMP-activated Protein Kinase
ANB	Alternate Nostril Breathing
ANG	Angiogenin
ANS	Autonomic Nervous System
ANT	Attentional Network Task
ApoAII	Apolipoprotein A II
AR	Aortic Regurgitation
ARBs	Angiotensin II Receptor Blockers
ARC	Hypothalamic Arcuate Nucleus
ARIC	Atherosclerosis Risk in Communities
ARNI	Angiotensin Receptor blockade with Neprilysin Inhibition
AS	Ankylosing Spondylitis
AS	Aortic Stenosis
ASCVD	Atherosclerotic Cardiovascular Disease

A CT	Arterial Cain Laboling
ASL ASPC	Arterial Spin Labeling
ASPC ATP III	American Society for Preventive Cardiology Adult Treatment Panel III
AUDIT	Alcohol Use Disorder Identification Test
AUDIT	Atrioventricular
AV	Atrio-ventricular Node
AVR	Aortic Valve Replacement
AYK	Ananda Marga Yoga
AYUSH	Ayurveda, Yoga, Unani, Siddha, Homeopathy
BA	Breathing Awareness
BBS	Berg Balance Scale
BDI-II	Beck Depression Inventory-II scale
BDNF	Brain-Derived Neurotrophic Factor
BDNP	Brain-derived Natriuretic Peptide
BE	Energy Balance
BER	Base Excision Repair
BF%	Body Fat Percentage
BFM	Body Fat Mass
BIA	Bioelectrical Impedance
BMI	Body Mass Index
BNP	Brain Natriuretic Peptide
BP	Blood Pressure
BPD	Biliopancreatic Diversion
BPD/DS	Biliopancreatic Diversion with Duodenal Switch
BPM	Beats Per Minute
BSX	Brain-Specific Homeobox Domain
BW	Body Weight
CABG	Coronary Artery Bypass Grafting
CAD	Coronary Artery Disease
CAG	Coronary Angiography
CAM	Complementary and Alternate Medicine
CaMKK2	Calcium/Calmodulin-dependent Protein Kinase Kinase 2
CBF	Cerebral Blood Flow
CDC	US Centers for Disease Control and Prevention
CDS	Cardiac Depression Scale
CFR	Coronary Flow Reserve
CG	Control Group
CGI-S	Clinical Global Impression Severity
CHD	Coronary Heart Disease
CHF	Congestive Heart Failure
CI	Confidence Interval
CIA	Chronic Inflammatory Arthritis
cIMT	Carotid Intimal Thickness
CKD	Chronic Kidney Disease
CM	Control Meditation
CMP CNP	Cardiomyopathy Chandra Nadi Dranavama
CNP	Chandra Nadi Pranayama
CO	Central Nervous System Canola Oil
CO	Cardiac Output
COPD	Chronic Obstructive Pulmonary Disease
COWS	Clinical Opiate Withdrawal Scale
COX-2	Cyclooxygenase 2
CPGs	Clinical Practice Guidelines
CPT	Carnitine Palmitoyltransferase
CR	Cardiac Rehabilitation
CRA	Comparative Risk Assessment
	•
CREB	cAMP Response Element-Binding Protein

CRF	Cardiorespiratory Fitness
CRF	Corticotrophin-Releasing Factor
CRH	Corticotrophin-Releasing Hormone
CRP	C-Reactive Protein
CRT	Cardiac Resynchronization Therapy
CRT-D	Cardiac Resynchronization Therapy with Defibrillator
CS	Coronary Sinus
CSA	Chronic Stable Angina
CSD	Cardiac Sympathetic Denervation
CSF	Cerebral Spinal Fluid
CSMMU	Chhatrapati Shahuji Maharaj Medical University (Formerly King George's Medical University)
CSP	Cortical Silent Period
CT CT CAC	Computed Tomography
CT CAG CT-FFR	Computed Tomography Coronary Angiography
CTLA4	Computed Tomography-derived Fractional Flow Reserve
CTRA	Cytotoxic T-Lymphocyte-Associated protein 4 Conserved Transcriptional Response to Adversity
CUD	Cannabis Use Disorder
CUD	Cocaine Use Disorder
CV	Cardiovascular
CVA	Cerebrovascular Accident
CVC	Comprehensive Valve Center
CVD	Cardiovascular Disease
CVEs	Cardiac Vascular Events
CVH	Cardiovascular Health
CVPR	Cardiovascular and Pulmonary Rehabilitation
CVRFs	Cardiovascular Risk Factors
СҮР	Common Yoga Protocol
D-MARDs	Disease-Modifying Anti-Rheumatic Drugs
D-TGAs	D-Transposition of Great Arteries
DAG	Directed Acyclic Graph
DALY	Disability Adjusted Life-Years
DAMP	Damage-Associated Molecular Patterns
DAN	Dorsal Attention Network
DASH	Dietary Approaches to Stop Hypertension
DASI	Duke Activity Status Scale
DASS-21	Depression Anxiety Stress Scale
DAYS	Diabetes and Yoga Study
DBP	Diastolic Blood Pressure
DC	Direct Cardioversion
DHA	Docosahexaenoic Acid
DHEAS	Dehydroepiandrosterone Sulfate
DLCO	Diffusion Capacity of the Lungs for Carbon Monoxide
DLPFC	Dorsolateral Prefrontal Cortex
DM	Diabetes Mellitus
DM DMN	Type II Diabetes Mellitus
DNA	Default Mode Network Deoxyribonucleic Acid
Do-P	Double Product
D0-F DPP	Diabetes Prevention Program
DPP-4i	Dipeptidyl Peptidase-4 Inhibitor
DPPOS	U.S. Diabetes Prevention Program Outcomes Study
DPS	Diabetes Prevention Study
DREAM	Diabetes REduction Approaches with ramipril and rosiglitazone Medications
DSM-5	Diagnostic and Statistical Manual-5
DSM-IV	Diagnostic and Statistical Manual-IV
DTV	Device-Treated Ventricular Events

DUDIT	Due Les Disorders Identification Test
DUDIT DVD	Drug Use Disorders Identification Test Double Vessel Disease
DYD DYS	Diabetes Yoga Protocol
EASD	European Association for the Study of Diabetes
EC SOD	Extracellular Superoxide Dismutase
ECG	Electrocardiography
ECO	Executive Control Network
EDs	Eating Disorders
EDS	End Diastolic Dimension
EEG	Electroencephalography
EGIR	European Group for the study of Insulin Resistance
EKG	Electrocardiography
ELR	External Loop Recorder
EMG	Electromyography
EMS	Emergency Medical Services
ENDS	Electronic Nicotine Delivery Systems
ENNDS	Electronic Non-Nicotine Delivery Systems
EPs	Evoked Potentials
EPA	Eicosapentaenoic Acid
EPIC	European Prospective Investigation into Cancer and Nutrition
EPS	Electrophysiological Studies
EQ-QOL	European Quality of Life
ERO	Effective Regurgitant Orifice
ERPs	Event-Related Potentials
ES	Eisenmenger Syndrome
ESC	European Society of Cardiology
ESC/EAS	European Society of Cardiology/European Atherosclerosis Society
ESC/ESH	European Society of Cardiology and European Society of Hypertension
ESD	End Systolic Dimension
ESR	Erythrocyte Sedimentation Rate
EULAR	European League Against Rheumatism
FA	Fatty Acid
FB	Fast Breathing
FBG	Fasting Blood Glucose
FBS	Fasting Blood Sugar
FDA	Food and Drug Administration
FDS	Forward Digit Span
FEC	Functional Exercise Capacity
FFA	Free Fatty Acid
FH	Familial Hyperlipidemia
FMC	First Medical Contact
fMRI	Functional Magnetic Resonance Imaging
FOX01	Forkhead Box 1
FRS	Framingham Risk Score
FS	Flourishing Scale
FVC	Forced Vital Capacity
GABA	Gamma-amino Butyric Acid
GAD	Generalized Anxiety Disorder
GBD	Global Burden of Disease
GCs	Glucocorticoids
GDM	Gestational Diabetes Mellitus
GDMT	Guideline-Directed Medical Therapy
GDS15	Geriatric Depression Scale-15
GH	Growth Hormone
GHDx	Global Health Data Exchange
GI	Glycemic Index Chyaemia Load
GL	Glycemic Load Glinide
GLN	Gilline

GLP-1 RA	Glucagon-like Peptide-1 Receptor Agonist
GM	Gray Matter
GMV	Gray Matter Volume
GP	Ganglionated Plexus
GPCR	G-protein-Coupled Receptor
GR	Glutathione Reductase
GSH	Glutathione
GST	Glutathione S-transferase
GXT	Graded Exercise Test
HAM-A	Hamilton Anxiety Rating Scale
HAM-D	Hamilton's Depression Rating Scale
HAQ-DI	Health Assessment Questionnaire Disability Index
HbA1c	Glycosylated Hemoglobin
Hbdiff	Hemoglobin difference
HC	Hip Circumference
HDAC	Histone Deacetylase
HDL	High-Density Lipoprotein
HF	Heart Failure
HFimpEF	Heart Failure with Improved Ejection Fraction
HFmrEF	Heart Failure with Mildly Reduced Ejection Fraction
HFpEF	Heart Failure with Preserved Ejection Fraction
HFrEF	Heart Failure with Reduced Ejection Fraction
HGP	Hepatic Glucose Production
HIV	Human Immunodeficiency Virus
HLA-B27	Human Leukocyte AntigenB27
HMGCoA	Hydroxymethylglutaryl-coenzyme A
HMPAO	Hexamethylpropyleneamine Oxime
HOMA-IR	Homeostatic Model Assessment for Insulin Resistance
HPA	Hypothalamic Pituitary Adrenal Axis
HR	Hazard Ratio
HR UR Oal	Heart Rate
HR-QoL HRV	Health-Related Quality of Life
hs-CRP	Heart Rate Variability Highly Sensitive C Reactive Protein
HsTnI	Highly Sensitive Troponin I
HTN	Hypertension
НТР	Heated Tobacco Product
НҮ	Hathayoga
I/G Ratio	Insulin/Glucagon Ratio
IAS	Interatrial Septum
ICD	International Classification of Diseases
ICD	Implantable Cardioverter Defibrillator
ICD-10	International Classification of Diseases, 10th Revision
ICMR-INDIAB	Indian Council of Medical Research-India Diabetes
ICPPR	International Council of Cardiovascular Prevention and Rehabilitation
IDF	International Diabetes Federation
IDL	Intermediate Density Lipoprotein
IFG	Impaired Fasting Glucose
IFN	Interferon
IGT	Impaired Glucose Intolerance
IHD	Ischemic Heart Disease
IKK	Inhibitor of Nuclear Factor-κB Kinase
IL	Interleukin
IL-6	Interleukin-6
ILR	Implantable Loop Recorder
IMT	Intima-Media Thickness
INR	Indian Rupee

IR	Insulin Resistance
IRF	Interferon Regulatory Factor
IRFs	Interferon Response Factors
ISH	International Society of Hypertension
IV	Inverse Variance
IV	Intravenous
IVC	Inferior Vena Cava
IVS	Interventricular Septum
JD	Japan Diet
K10	Kessler Psychological Distress Scale
ККМ	Kirtan Kriya Meditation
KOR	Kappa Opioid Receptor
LA	Linolenic Acid
LCDs	Low-Calorie Diets
LCT	Letter Cancellation Test
LDL	Low Density Lipoprotein
LDL-C	Low Density Lipoprotein Cholesterol
LF/HF Ratio	Low Frequency/High Frequency Ratio
LHPA	Limbic Hypothalamic Pituitary Adrenal Axis
LNB	Left Nostril Breathing
Low-MEE	Low Myocardial Mechano-Energetic Efficiency
LPFC	Left Prefrontal Cortex
LPS	Lipopolysaccharide
LV and RV	Left Ventricle and Right Ventricle
	Left Ventricle Left Ventricular Assist Device
LVAD LVEDP	Left Ventricular Assist Device Left Ventricular End Diastolic Pressure
LVEDV	Left Ventricular End Diastolic Viewe
LVEF	Left Ventricular Ejection Fraction
LVH	Left Ventricular Hypertrophy
MACEs	Major Adverse Cardiac Events
MAP	Mean Arterial Blood Pressure
MASALA	Mediators of Atherosclerosis in South Asians Living in America
MB	Moderator Band
MBIs	Mind Body Interventions
MBSR	Mindfulness-Based Stress Reduction
MBTs	Mind Body Therapies
MC3R	Melanocortin Receptor 3
MCP-1	Monocyte Chemotactic Protein-1
MCS	Mechanical Circulatory Support
MDA	Malondialdehyde
MDD	Major Depressive Disorder
MDMA MEG	3, 4-Methylenedioxymethamphetamine Magnetoencephalography
MEG	Metabolic Equivalents
MET	Metabolic Equivalents
Meth	Methamphetamine
MetS	Metabolic Syndrome
MI	Myoinositol
MI	Myocardial Infarction
MINOCA	Myocardial Infarction with Nonobstructive Coronary Arteries
MLwHFQ	Minnesota Living with Heart Failure Questionnaire
MM	Mindfulness Meditation
MnSOD	Manganese Superoxide Dismutase
MnSOR	Methionine Sulfoxide Reductase
MNT	Medical Nutrition Therapy
MONICA	Monitoring of Trends and Determinants in Cardiovascular Disease
MRC	Medical Research Council of Great Britain

MRI	Magnetic Resonance Imaging
MRS	Magnetic Resonance Spectroscopy
MS	Mitral Stenosis
MSU	Monosodium Urate
MT	Medical therapy
mtDNA	Mitochondrial DNA
mTOR	Mammalian Target of Rapamycin
MUFA	Mono Unsaturated Fatty Acid
MV	Mitral Valve
MVA	Mitral Valve Area
MVR	Mitral Valve Replacement
NA	Not Available
NAA	N-acetyl aspartate
NAD	Nicotinamide Adenine Dinucleotide
NAVIGATOR	Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research
NCCIH	National Center for Complementary and Integrated Health
NCD	Non-Communicable Disease
NCEP	National Cholesterol Education Program
NCEP:ATP III	National Cholesterol Education Program Adult Treatment Panel III
NCHS	National Center for Health Statistics
NCS	Nerve Conduction Studies
NE NET	Norepinephrine Neutrophil Extracellular Trap
NET NF-kB	Nuclear Factor Kappa B
NFHS-3	National Family Health Survey-3
NHANES	National Health and Nutrition Examination Survey
NHIS	National Health Interview Survey
NHLBI	National Heart, Lung, and Blood Institute
NICE	National Institute for Health and Care Excellence
NIDDM	Non-Insulin–Dependent Diabetes Mellitus
NMA	Network Meta-Analysis
NO	Nitric Oxide
NOS	Nitric Oxide Synthetase
NPY/AgRP	Neuropeptide Y/Agouti-Related Peptide
NS	Nervous System
NSAIDs	Non-Steroidal Anti-Inflammatory Drugs
NSTEMI	Non-ST-segment Elevation Myocardial Infarction
NTProBNP	N-terminal Pro B-type Natriuretic Peptide
NYHA	New York Heart Association
ODS	Opioid Dependence
OGTT	Oral Glucose Tolerance Test
OHQ	Oxford Happiness Questionnaire
00	Olive Oil
OS	Oxidative Stress
OSA	Obstructive Sleep Apnea
OUDs	Opioid Use Disorders
OXPHOS n mTOP	Oxidative Phosphorylation Phosphorylated Mammalian Target of Rapamycin
p-mTOR PA	
PA	Physical Activity Pulmonary Artery
PAD	Peripheral Artery Disease
PAF	Paroxysmal Atrial Fibrillation
РАМРК	Phosphorylated AMP-Activated Protein Kinase
PANAS	Positive and Negative Affect Scale
PASP	Pulmonary Artery Systolic Pressure
PAX	Parasternal Long Axis view
РВМС	Peripheral Blood Mononuclear Cell
PCI	Percutaneous Intervention

DCOG	
PCOS PD	Polycystic Ovarian Syndrome Panic Disorder
PD PD	Parkinson's Disease
PE	Pulmonary Embolism
PET	Positron Emission Tomography
PFC	Prefrontal Cortex
PFT	Pulmonary Function Test
PGC1a	Peroxisome Proliferator-Activated Receptor-γ Coactivator
РНР	Personalized Health Planning
РНТ	Pressure Half Time
PISA	Proximal Hypovelocity Hemispheric Surface Area
PM	Progressive Relaxation Meditation
PMBC	Percutaneous Mitral Balloon Commissurotomy
PNMT	Phenylethanolamine N-methyltransferase
PNS	Parasympathetic Nervous System
POTS	Postural Tachycardia Syndrome
ΡΡΑΚγ	Peroxisome Proliferator-Activated Receptor-Gamma
PPBG	Postprandial Blood Glucose
PPBS	Postprandial Blood Sugar
PPI	Permanent Pacemaker Implantation
PROBE	Prospective Randomized Open Blinded End-Point
PROMs	Patient-Related Outcome Measures
PsA	Psoriatic Arthritis
PsO	Psoriasis
PTCA	Percutaneous Transluminal Coronary Angioplasty
PTSD	Post-Traumatic Stress Disorder
PUFA	Poly Unsaturated Fatty Acid
PURE PVs	Prospective Urban and Rural Epidemiological Study Pulmonary Veins
r vs PVCs	Premature Ventricular Contractions
QoL	Quality of Life
QR	Quick Release
QTd	QT Dispersion
RA	Rheumatoid Arthritis
RAAS	Renin-Angiotensin-Aldosterone System
RAS	Renin–Angiotensin System
RBO	Rice Bran Oil
rCBF	Regional Cerebral Blood Flow
rCMRGlc	Regional Cerebral Metabolic Rate of Glucose Consumption
RCT	Randomized Controlled Trial
RDS	Reverse Digit Span Test
RES	Restorative Hatha Yoga
RF	Rheumatoid Factor
RF	Regurgitant Fraction
RFA	Radio Frequency Ablation
RFFT RM	Ruff Figural Fluency Test
RM	Rajyoga Meditation Relaxing Music
RMSSD	Root Mean Square of Successive Differences between normal heartbeats
RNB	Right Nostril Breathing
RNS	Reactive Nitrogen Species
ROI	Region of Interest
ROM	Range of Motion
ROS	Reactive Oxygen Species
RPFC	Right Prefrontal Cortex
RPP	Rate Pressure Product
RSNs	Resting-State Networks
RSPV	Right Superior Pulmonary Vein
RVol	Regurgitant Volume
RYGB	Roux-en-Y Gastric Bypass
S/P	Status Post

SAEs	Serious Adverse Events
SAN	Sino-atrial Node
SAT	Scholastic Assessment Test
SAX	Parasternal Short Axis view
SB	Slow Breathing
SBP	Systolic Blood Pressure
SBWI	Standard Behavioral Weight-loss Intervention
SCD	Sudden Cardiac Death
SD SDNNi	Standard Deviation
SEAR	Standard Deviation of NN intervals Index
SEAR	South East Asian Region Social Economic Status
SF12	Short-Form Health Survey
SFA SFA	Saturated Fatty Acid
SGLT2i	Sodium-Glucose Transporter 2 Inhibitor
sHLA-G	Soluble Human Leukocyte Antigen
SICI	Short Intra-Cortical Inhibition
SIHD	Stable Ischemic Heart Disease
SIRT1	Sirtuin1
SKY	Sudarshan Kriya Yoga
SMART	Specific, Measurable, Achievable, Realistic, Time-limited
SMC	Smooth Muscle Cell
SNS	Sympathetic Nervous System
SNS-HPA	Sympathetic Nervous System–Hypothalamic Pituitary Adrenal Axis
SOD	Superoxide Dismutase
SpAs	Spondyloarthritides
SPANE	Scale of Positive and Negative Experience
SPECT	Single Photon Emission Computed Tomography
SR	Systematic Review
SSRI	Selective Serotonin Reuptake Inhibitors
STAI	State-Trait Anxiety Inventory
STEMI	ST Elevation Myocardial Infarction
STS	Society of Thoracic Surgeons
SU	Sulfonylurea
SUD	Stimulant Use Disorder
SVC	Slow Vital Capacity
SVC	Superior Vena Cava
SVT	Supraventricular Tachycardia
SY	Sahaja Yoga
T2DM	Type 2 Diabetes Mellitus
ta-VNS	Transcutaneous Auricular Vagal Nerve Stimulation
TAC	Total Antioxidant Capacity
TAK1	Transforming growth factor- β -activated kinase 1
TAS	Total Anti-Oxidant Stress
TAVI	Transcatheter Aortic Valve Implantation
TBs	Tibetan Buddhists Tuberculosis
TB TC	Total Cholesterol
TCIM	Traditional, Complementary, and Integrative Medicine
tDCS	Transcranial Direct Current Stimulation
TdP	Torsades de Pointes
TEE	Total Energy Expenditure
TEI	Total Energy Intake
TF	Transfemoral
TGs	Triglycerides
TGF-β	Transforming Growth Factor β
TLCs	Therapeutic Lifestyle Changes
TLR9	Toll-Like Receptor 9
TM	Transcendental Meditation
ТМА	Trimethylamine

TMAO	This delay in Orithm
TMAO	Trimethylamine Oxidase
TMS	Transcranial Magnetic Stimulation
TNF	Tumor Necrosis Factor
TNF-a	Tumor Necrosis Factor-a
TOF	Tetralogy of Fallot
TOS	The Obesity Society
TPM	Temporary Pacing
TPR	Total Peripheral Resistance
TRAF6	TNF Receptor-Associated Factor 6
TrkB	Tropomyosin Receptor Kinase B
TSH	Thyroid Stimulating Hormone
ТТА	Trail making Test 'A'
ТТВ	Trail making Test 'B'
TVD	Triple Vessel Disease
TZD	Thiazolidinedione
UA	Unstable Angina
UCP2	Uncoupling Protein 2
UK	United Kingdom Unilateral Nostril Breathing
UNB UNDOC	United Nation Office on Drugs and Crime
UPRmt	Mitochondrial Unfolded Protein Response
USA	United States of America
VaD	Vascular Disease
VAS	Visual Analogue Scale
VBCT	Voxel-Based Cortical Thickness
VDCI	Vena Contracta
VEGF	Vascular Endothelial Growth Factor
VF	Ventricular Fibrillation
VHD	Valvular Heart Disease
VIN	Vinyasa Yoga
VKA	Vitamin K Antagonist
VLCDs	Very-Low Calorie Diets
VLDL	Very Low Density Lipoprotein
VMH	Hypothalamic Ventromedial Nucleus
VNS	Vagal Nerve Stimulation
VT	Ventricular Tachycardia
VVS	Vasovagal Syncope
WAIS-RNI	Wechsler Adult Intelligence Scale-Revised Neuropsychological Instrument
WC	Waist Circumference
WHO	World Health Organization
WHOQOL-BREF	World Health Organization Quality of Life Scale-short version
WHR	Waist to Hip Ratio
WHYES	Women's Health, Yoga and Education Study
YB	Yoga Breathing
YG	Yoga Group
YLD	Years Lived with Disability
YLL	Years of Lives Lost
YLP	Yoga-Based Lifestyle Protocol
Yoga-CaRe	Yoga-based Cardiac Rehabilitation
YOMI	Yin yoga + psychoeducation and mindfulness practice
YPA Scale	Yoga Performance Assessment Scale
YT	Yoga Treatment
γ-ΒΒ	γ-Butyrobetaine

Index

Note: "Page numbers followed by f indicate figures, t indicates tables."

A

Acute coronary syndrome (ACS), 9, 111, 354 Acute myocardial infarction (AMI), 14, 469f Acute phase, 438 Acute phase insulin release (AIR), 391-392 Acyanotic diseases, 19 Aerobic exercises, 39 African American, 148 Age-specific prevalence, 256 Alcohol, 295 Alcohol-use disorders, 485 Almonds, 409 Alternative holistic approach, 456-457 Alzheimer's dementia, 330 Alzheimer's disease (AD), 319, 391, 392f Ambulatory blood pressure monitoring (ABPM), 127-129 American Association of Cardiovascular and Pulmonary Rehabilitation (AACPR), 437 American Association of Clinical Endocrinology (AACE), 249 American College of Cardiology/American Heart Association (ACC/AHA), 127 American Diabetes Association (ADA), 161, 177 American Heart Association (AHA), 91, 99-102, 261f American Lung Association, 479-481 American Society for Preventive Cardiology (ASPC), 65 AMP-activated protein kinase (AMPK), 49 - 50Amphetamines, 479 Analysis of covariance (ANCOVA), 466t Angiogenin (ANG), 320-321 Angiotensin receptor blockade with neprilysin inhibition (ARNI), 16-17 Antihypertensive therapy, 136-138, 140 Anxiety disorders, 371-381, 371t-372t Aortic stenosis (AS), 17 Apathya Ahara, 393 Apo-lipoprotein B (apoB-LDL), 455 Arrhythmias, 14-16, 40-43 Arterial hypertension, 161 Arterial stiffness, 241 Asana, 381 Atherosclerosis, 28-29, 330, 405-406 Atherosclerotic cardiovascular disease (ASCVD), 9, 405, 414t

Atrial fibrillation (AF), 16, 291, 292t-293t, 376 autonomous system, 293-298 epidemiology, 291 pathogenesis, 291 yoga, 298-300 Atrioventricular node (AVN), 3 Attentional Network Task (ANT), 330 Autoimmune-mediated inflammatory arthritis, 339 Autonomic dysfunction, 298, 444-445 Autonomic mechanism, 297f Autonomic nervous system (ANS), 37-39, 47-48, 194-195, 279-280, 293, 298, 374f, 391-392 Autonomous system (ANS), 40 Axial diffusion-weighted MRI, 307f Ayurveda, 395-396 Ayurvedic alternative systems, 393-399 Ayurvedic dietary plans, 394 Ayurvedic/yogic diet, 393-394

B

Bandhas, 264 Bariatric surgery, 223 Behavioral Risk Factor Surveillance System data, 440 Beta-endorphin, 323-324 Bhastrika Pranayama, 382 Black rice, 410-411 Blood lipids, 425 Blood pressure, 119, 127 Blood-retinal barrier, 208 Blood supply of heart, 3, 6f Body mass index (BMI), 138, 181-182 Bradyarrhythmias, 15 Brain-derived neurotrophic factor (BDNF), 320 Brain metabolites, 80-81 oxygenation, 325 stress response systems, 369-371 structure and function, 358 Brain natriuretic peptide (BNP), 16-17

С

cAMP response element-binding (CREB) protein, 47–48 Cannabis-use disorder (CUD), 479 Canola oil (CO), 409

Carbohydrate-restricted diets, 408-409 Carbohydrates, 408-411, 413 Cardiac autonomic dysfunction, 209 Cardiac autonomic nervous system, 279 Cardiac autonomic system, 282t Cardiac cycle, 5 Cardiac Depression Scale (CDS), 501 Cardiac disease, 355-357 Cardiac embryology, 5 Cardiac neuroanatomy, 279-280 Cardiac outcomes, 354 Cardiac physiology, 5-9 Cardiac rehabilitation (CR), 37, 437-439, 438f, 441f, 451-453 global use, 440-441 guidelines, 440 outcomes, 439-440 phases, 438-439 yoga, 443-445 acceptability, 444 neuroendocrine effects, 443-444 Cardiology, 68 Cardiometabolic risk factors, 28 Cardiovascular and all-cause mortality, 429 - 430Cardiovascular death, 27 Cardiovascular diseases (CVDs), 27, 37, 44, 59, 61-65, 88-89, 147, 151-152, 208, 217, 249, 255t, 269, 338, 342-344, 353, 358-361, 367-381, 379t-380t, 390, 403, 422-423, 437, 453 continuum across lifespan, 28-30 depression course, 354 epidemiology, 27 inflammatory basis, 455-456 management, 30-31 mental health comorbidities, 367 prevention, 493 public health approaches, 30 risk factors in India, 491 risk prevention, 405-407 risk reduction, 223 through yoga, 31-33 yoga mechanism in. See yoga mechanism Cardiovascular disorders, 9-22, 376 Cardiovascular health (CVH), 113, 430, 446t-447t, 465 Cardiovascular pathology, 263-264 Cardiovascular (CV) risk, 339

Cardiovascular risk factors (CVRFs), 338, 421, 423-426, 428 Carotid plaque formation, 339 Cellular metabolism, with yoga, 49-52 Centers for Disease Control and Prevention's (CDC), 68 Central nervous system (CNS), 52f, 279 Cerebral spinal fluid (CSF), 391 Cerebrovascular disease, 330-331 Chandra Anuloma Viloma pranayama, 382 Chandra nadi pranayama (CNP), 139 China diabetes report 2020-45, 182 Chronic hyperglycemia, 207 Chronic inflammatory arthritis (CIA), 337-339, 342-344 Chronic kidney disease, 136 Chronic stress, 28 Chronic stress-induced NF-KappaB activation, 367-369 Classic yoga system, 114 Clinical practice guidelines (CPGs), 196 Cluster subtraction, 328f Cocaine-use disorders, 486 Cochrane meta-analysis, 313 Cognitive-behavioral techniques, 223 Common Yoga Protocol (CYP), 320-321, 457 Communicable disease (CD), 453 Comorbid anxiety/stress, 381 Complementary and alternative medicine (CAM), 147, 269, 312 Comprehensive approach model, 446f Comprehensive risk management, 439-440 Computed tomography coronary angiography, 13 Congenital heart disease, 19-21 Congestive HF (CHF), 271 clinical benefits, 270 mechanism, 270 Conserved transcriptional response to adversity (CTRA), 48-49, 367-369 Convalescent phase, 438 Coronary angiogram, 119 Coronary artery bypass grafting (CABG), 353, 443, 454 Coronary artery disease (CAD), 9, 87, 111, 113, 131, 453 secondary prevention, 115-120, 122 Coronary heart disease (CHD), 59, 87, 105, 371-372, 405-406 Cortical inhibition (CI), 322 Cortical silent period (CSP), 322 Cortisol, 323-324 C-oryzanol, 409 Country-specific yoga guidelines, 174 C-reactive protein (CRP), 48 Cross-sectional study, 139, 241-242, 413 CT-derived fractional flow reserve (CT-FFR), 13 Cyanotic heart diseases, 19

D

Delphi recommendations, 344, 345t-346t Depression, 354-361

cardiovascular diseases (CVDs), 354 yoga, 358-359 Device-treated ventricular (DTV), 360 Dharana, 264 Dhvana, 264, 381 Diabetes, 91, 177, 294-295, 423-424, 492 ayurveda/yoga schools, 396 fruits, 395 lifestyle disorders, 390 lifestyle protocols, 393-394 pathogenesis, 177 Pathya (allowed food items) Ahara, 394 prevention, 170-173 risk, 161 seeds, 395 spices, 395 vegetables, 395 Diabetes mellitus (DM), 207, 390 Diabetes mellitus type 2 prevalence, 160f Diabetes Prevention Program (DPP), 161 Diabetic neuropathy, 208 Diabetic retinopathy, 208 Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V), 479 Diastolic blood pressure (DBP), 91, 298, 376, 495-496 Diet, 422-423 Dietary Approaches to Stop Hypertension (DASH) diet, 134-135, 408 Dietary carbohydrates, 422 Dietary fats, 413, 422 Dietary habits, 412-413, 492 Dietary patterns, 410, 412-413, 423 Dietary proteins, 422-423 Diet-induced risk, 421, 430 Diet patterns, 408 recommendations, 407t Directed acyclic graph (DAG), 368f Disability-adjusted life years (DALYs), 27, 88-89, 453 Distress tolerance (RCT/nonRCT), 242 Drug addiction cycle, 477-479 Drug-induced hypertension, 132t Dynamic yoga, 381 Dyslipidemia, 102, 493

E

Eating disorders (EDs), 399 Egg, 408–409 Electrical activity, 8 Electrocardiogram (ECG), 78 Electrocardiogram (EKG), 438–439 Electroncephalography (EEG), 78–79, 326 Electronic nicotine delivery systems (ENDSs), 478 Electronic nonnicotine delivery systems (ENNDSs), 478 Electrophysiology, 326 Emotionalism, 314 Endothelial dysfunction, 339 Endothelial function, 426 Environmental factors, 177

Epidemiology, 291 ESC/EAS Guidelines 2019, 407-408 Essential hypertension, 130 European Association for the Study of Diabetes (EASD), 198 European Group of Study for Insulin Resistance (EGIR), 249 European League Against Rheumatism (EULAR), 342, 344 European society of cardiology/European Atherosclerosis society (ESC/EAS), 415 Event-related potentials (ERPs), 326 Evoked potentials (EPs), 78-79, 326 Exercise-based cardiac rehabilitation (CR), 496-497 Exercise capacity, 119 External loop recorder (ELR), 15

F

Fats, 409, 411
Fermented or alcoholic liquids, 394
Fiber-rich carbohydrate foods, 413
Fluorescein angiography, 208
Food articles and spices, 394
Framingham Offspring Study, 405
Framingham risk scoring (FRS) system, 104, 235
Frank-Starling law, 8
Fruits, 394, 412
Functional foods, 412, 415
FunRich Database tool, 52–54

G

Gait, 310, 315 Gamma-aminobutyric acid (GABA) modulation, 76 system, 40, 322, 357 Ganglionated plexi (GP), 293, 296f Gender-specific prevalence, 255 Geographical regions-specific prevalence, 256 Geographic epidemiology, 61-65 Gestational diabetes mellitus (GDM), 161, 390 Global Burden of Disease (GBD), 88-89, 405 Global diabetes data, 181t Global disability-adjusted life years (DALYs), 252f Glucocorticoid receptor (GR), 47-48 Glycemic index (GI), 408-409 Glymphatics, 391 Gout, 340 Grains, 394 Gray matter volumes (GMV), 327 Guideline Directed Medical Therapy, 202 Gut microbiome, 425-426

Η

Hamilton Anxiety Rating Scale (HAM-A), 501 Hatha yoga, 147, 241–242, 466 Health assessment questionnaire disability index (HAQ-DI), 48 Health benefits, of yoga and exercise, 168t-169t Health physical activity recommendations, 164 Health-related quality, 299t, 377t Health-related quality of life (HR-QoL), 68, 138, 273 Health system-level barriers, 440-441 Healthy Dietary Pattern, 412-413 Healthy lifestyle habits, 413 Healthy plant-based diets, 425, 430 Heart disease, 3 anatomy, 3-5cardiac embryology, 5 cardiac physiology, 5-9 cardiovascular disorders, 9-22 Heart failure (HF), 16-17, 30, 40, 115, 353, 428 Heart rate (HR), 294-295 Heart rate variability (HRV), 68, 78, 139, 280-283, 442 Hemodynamic assessment, 299t, 378t Hemoglobin difference (Hbdiff), 325 Hepatic triglyceride accumulation, 41-43 HF with improved ejection fraction (HFimpEF), 16-17 HF with reduced ejection fraction (HFrEF), 16 - 17High-Fiber Pattern, 412-413 High-frequency (HF), 281 High-frequency HRV (HF), 358 High-sensitivity C-reaction protein (hsCRP), 40, 455 Hispanic communities, 148 Home-based cardiac rehabilitation, 441 Hormone insulin, 177 Hormones, 323-324 Human heart, 3-5, 4f Humming breath, 382 Hydrogen peroxide production, 50-51 Hypercholesterolemia, 403, 412 Hyperglycemia, 177 Hyperlipidemia, 405 Hypertension, 21-22, 39, 91, 134-136, 423, 492 Hyperuricemia, 340 Hypothalamo-pituitary-adrenal (HPA), 31, 37-39, 47-48, 105, 115, 160-161, 165, 312 Hypothalamo-pituitary axis, 396t

I

Immunological modulation, 76 Impaired glucose tolerance (IGT) phase, 159 Implantable cardioverter-defibrillator (ICD) system, 287f, 360 Improved glucose tolerance (IGT), 395 Inadequate exercise, 397 India, 404–405 Indian Council of Medical Research-India Diabetes study (ICMR-INDIAB), 492 Indus-Sarasvati civilization, 208 Inferior venae cava (IVC), 3 Inflammation, 102-104 Inflammatory biology, 52-54 Inflammatory cytokines, 323t, 340 Inflammatory markers, 119, 426 Inflammatory mechanisms, 28 Inflammatory pathways, 47-48, 357 Inflammatory pericardial diseases, 21 Inflammatory process, 340 Insulin resistance, 41–43 Interatrial septum (IAS), 3 Interferon regulatory factor (IRF), 51-52 Interferon response factors (IRFs), 324 Interleukin-1beta (IL1ß), 321 Interleukin-6 (IL-6), 455 International Classification of Diseases (ICD10), 337 International Council of Cardiovascular Prevention and Rehabilitation (ICCPR), 502 Intraventricular septum (IVS), 3 Ischemic heart disease (IHD), 9-14, 28, 37-39, 59-60, 427-428 Isotope dilution techniques, 217

Jackson Heart Study (JHS), 149

Κ

I

Kirtan kriya meditation (KKM), 324 Kriyas, 263

L

Laplace's law, 9 Large multisite randomized controlled trial, 260 LDL cholesterol levels, 410 LDL-lowering therapy, 415 Left bilateral surgical CSD, 286 Left prefrontal cortex (LPFC), 325 Left ventricular assist devices (LVADs), 16 - 17Left ventricular ejection fraction (LVEF), 119, 271, 438, 497 Lifestyle behavior change for diabetes prevention, 170-173 Lifestyle interventions, 406 diabetes, 163 Lifestyle modification (LSBM), 453 Lifestyle-related risk factors, 250-251 Limbic-hypothalamic-pituitary-adrenal (LHPA) axis, 323-324 Linolenic acid (LA), 413 Lipid profile, 119 pre and postintervention, 360f Low-density lipoproteins (LDLs), 87 Low-frequency (LF) fluctuations, 281 Low-GI diets, 408-409 Low myocardial mechano-energetic efficiency (low MEE), 342 L-type calcium channels, 293 Lung capacity, 119 LV ejection fraction (LVEF), 16-17

Μ

MACE reduction, 501 Magnetic resonance spectroscopy study, 81 Major depressive disorder (MDD), 353 Malondialdehyde (MDA), 320 Manganese superoxide dismutase (MnSOD), 50 - 51Mean arterial blood pressure (MAP), 130 Meditation, 281 Melatonin, 323-324 Mental health comorbidities, in CVDs, 367 Metabolic disorders, 261 Metabolic health, 261-262 Metabolic risk factors, 258-260 Metabolic syndrome (MetS), 41-43, 91, 226, 249-250, 250f, 253, 261, 331 Metformin therapy, 173 Methamphetamine (METH), 479 Methionine sulfoxide reductase (MnSOR), 50 - 51Middle-income countries, 440 Mind-body interventions (MBI), 269-270 Mind-body therapies (MBT), 37-39 Mindfulness-based stress induction (MBSR), 51 - 52Mind sound resonance technique (MSRT), 457 Minnesota Living with Heart Failure Questionnaire (MLwHFQ), 270 Mitochondrial DNA (mtDNA), 50-51 MitraClip percutaneous therapy, 18 Mitral regurgitation, 18 Modalities, 162-165 Moderate-intensity physical activity, 164 Modern neurophysiological research tools, 77 Modern reductionist approach, in medicine, 454-455 Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA), 61 Monosodium urate (MSU), 338 Monounsaturated fatty acid (MUFAs), 411 Mortality recommendations, 173 Motor stiffness, 315 Motor weakness, 310, 315 Mudra, 264 Multiple epidemiological risk factors, 67 - 68Myocardial infarction (MI), 88t, 371-372 Myocardial infarction with nonobstructive coronary arteries (MINOCAs), 9 Ν Nateglinide and Valsartan in Impaired

Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR), 165 National Center for Complementary and Integrative Health (NCCIH), 75 National Center for Health Statistics (NCHS), 68 National Centre for Complementary and Integrative Health (NCCIH), 47

National diabetes statistics report, 183f

National Family Health Survey-3 (NFHS-3), 492 National Health and Nutrition Examination Survey (NHANES), 404 National Health Interview Survey (NHIS), 68, 147-148 National Institute for Health and Care Excellence (NICE), 127 Natural products, 394 Nephropathy, 207 Nerve conduction studies (NCS), 208 Nervous system, 482-484 Neural activation, 80 Neurobiology of yoga, 75 brain metabolites, 80-81 ECG. 78 electroencephalography (EEG), 78-79 evoked potentials, 78-79 functional neuroimaging studies, 79-80 heart rate variability, 78 imaging studies, 79 magnetic resonance spectroscopy study, 81 neural activation, 80 neurobiological mechanisms, 75-76 neuroplasticity, 79 neurotransmitters, 80-81 stress, 81 structural/morphological neuroimaging studies, 79 systematic studies, 77 Neurochemistry, 357 Neuroendocrine mechanism, 47-48 Neuropathy, 208 Neurophysiological level, 482 Neurophysiology, 358 Neuroplastic effects, 76 Neuroplasticity, yoga effects on, 79 Neurotransmitters, 80-81 Neurotrophic factor, 320 Nicotine-use disorders, 484-485 Niyama, 262-263 Noncommunicable diseases (NCDs), 59, 159-160, 249, 367 Non-high-density lipoprotein (HDL) cholesterol, 65 Nonpharmacologic therapy, 134-135, 136t Nonpulmonary foci, 291 Nonrandomized trials, 139 Norepinephrine (NE), 367-369 N-terminal proB-type natriuretic peptide (NT proBNP), 271 Nuclear factor-kappa B (NF-кβ), 47-48 Nutrients, 410, 413 Nutritional interventions, 163-164 Nuts, 409, 413

Ο

Obese adults, yoga effect in, 237t Obesity, 99, 217, 424, 493 Obstructive sleep apnea, 293–294 Oils, 394, 409 Oilseeds, 411, 413 OM Chanting, 382 One-time studies, 495 Ophthalmoscopy, 208 Opioid dependence (ODS), 485 Opioid-use disorders (OUDs), 485–486 Ornish protocol, 498f Oryza sativa, 394 Oxford Happiness Questionnaire (OHQ), 327 Oxidative phosphorylation (OXPHOS), 50–51 Oxidative respiratory-chain reactions, 50–51 Oxidative stress, 41–43, 102–104, 357–358 markers, 357–358

P

Palliative care settings adopting complementary therapies, 463-465 complementary therapies, in palliative care, 466 definition, 463 epidemiology, 463 yoga role, 468-471 therapy, 466-468 Parasympathetic motor neurons, 279 Parasympathetic nervous systems, 243, 279, 312 Parkinson's disease (PD), 48 Paschimottanasana, 214 Pathogenesis, 130 Pathophysiological mechanism, 295 Pathophysiological risk factors, 251-252 Pathya Ahara for diabetics, 394-395 Pericardial diseases, 21 Peroxisome proliferator-activated receptorgamma (PPARy), 49-50 Peroxisome proliferator-activated receptor-y coactivator (PGC1a), 49-50 Persistent cancer-related fatigue, 470t Pharmacological drugs, 27 Pharmacological interventions, 164-165 Pharmacologic intervention recommendations, 173 Pharmacologic therapy, 135-136 Pharmacotherapy, 319 Phaseolus aureus, 394 Physical activity, 164, 492 Physical therapy interventions-physical fitness, 311f Physiotherapy-based LSP (PTLSP), 457 Phytosterols, 415 Plant-based diets, 412, 421-430 Plant-predominant diets, 422 Plasma lipoprotein, 119t Portfolio dietary pattern, 408 Positron-emission tomography (PET), 328 Postcardiovascular events (CVEs), 37 Poststroke complications, 310 Poststroke spasticity, 310 Post traumatic stress disorder, 373-375 Postures, 137 Pranayama, 40, 263-264, 283, 381 Prediabetes epidemiology, 161 Premature atherosclerosis, 208 Premature ventricular complexes (PVCs), 286f

Presurgical rehabilitation, 451 Probiotic-contained milk formula (PMF), 411 Probiotic yogurt, 408-409 Procoagulant status, 102-104 Professional medical societal guidelines, 421 Prognosis, 342 Prospective trials, 139 Proteins, 54t, 408-409, 411 Psychological stress, 48-49, 209 Psychological well-being, 313-314 Psycho-neuroendocrine immune mechanism. 195 Psychosocial stress, 99-102 Psychosomatic harmonizing effects, 389 Pulmonary valve diseases, 18 Pulmonary vein ganglia, 279-280 Pulmonary veins (PVs), 3 Pulses, 394, 408-409

Q

QT dispersion, 286 Quality improvement programs, 30 Quality of life (QoL), 117, 270, 291, 310, 376, 439–440, 454 Quality of life (RCT/nonRCT), 242 Quasi-experimental study, on metabolic syndrome, 260

R

Race/ethnic-specific prevalence, 253 Rajyoga meditation (RM), 327 Randomized clinical trials (RCTs), 408 Randomized controlled trials (RCTs), 37-39, 91, 118t, 134-135, 138-139, 163, 226-230, 231t-234t, 258-260, 270, 371-372, 376, 397, 410-412, 442, 495, 499t-500t Randomized mechanistic trial, 443-444 Rate pressure product (RPP), 271 Regional cerebral blood flow (rCBF), 325 Regulated breathing, 137 Rehabilitation programs, 451, 459 Relaxing music (RM), 324 Renin-angiotensin system (RAS), 162 Retinopathy, 208 Rheumatoid arthritis (RA), 339-340, 342-343 Rice bran oil (RBO), 409 Right attitudes cultivation, 262 Right prefrontal cortex (RPFC), 325

S

Salivary cortisol, 324 Sattvic dietary pattern, 398 Secondary hypertension, 130 Secondary prevention CAD, 227, 235 Secondary prevention therapies, 113 Seeds, 394 Serious adverse events (SAEs), 140 Serum lipid fractions, 404t Single-agent therapy, 136 Single-arm prepost design, 376–381 Single-arm trials, 139 Single-group studies, 495 Single-photon emission CT (SPECT), 328 Sinoatrial node (SAN), 3 Smoking, 295, 492 Smoking cessation, 99 Smooth muscle cells (SMCs), 87 Socioeconomic class, 150t Sodium-glucose transporter-2 inhibitors (SGLT2i), 16-17 South Asia, 404-405 Soya milk, 408-409 Spondyloarthritides (SpA), 340 Stable ischemic heart disease (SIHD), 9 State-Trait Anxiety Inventory (STAI), 375 ST-elevation MI (STEMI), 443 Stress, 367-371, 373-381 management, 113 neuroanatomy, 370f system, 369f Stroke, 309t, 429 economic burden, 306-307 epidemiology, 305 etiology, 307-309 management, 309 psychological well-being, 313-314 Structural/morphological neuroimaging studies, 79 Substance-use disorders, 486 Sudarshan Kriya Yoga (SKY), 320 Sukha Pranayama, 382 SukshmaVayama, 381 Superior venae cava (SVC), 3 Superoxide dismutase (SOD), 258, 320 Survey methods, 65-67 Surya Namaskara, 263 Sympathetic motor neurons, 279 Sympathetic nervous activity (SNS), 47-48 Sympathetic nervous system (SNS), 48-49, 165, 279, 312 Sympathetic predominance, 442 Syncope, 283-284 Systolic blood pressure (SBP), 91, 298, 495-496

Τ

Tachyarrhythmias, 15-16 Telomerase gene expression, 39 Tentative yoga-based lifestyle regimen, 214-215 Therapeutic lifestyle changes (TLCs), 416f TMA-oxidase (TMAO), 425-426 Tobacco-use disorder, 478 Tocotrienols, 409 Torsades de Pointes (TdP), 15-16 Total antioxidant capacity (TAC), 48-49 Total cholesterol (TC), 404 Total energy expenditure (TEE), 397 Total energy intake (TEI), 397 Traditional Asian exercises (TAEs), 277 Transcendental meditation (TM), 91, 209, 315, 324 Transcutaneous auricular vagal nerve stimulation (taVNS), 76

Tree nuts, 409 Tricuspid valve diseases, 18 Trimethylamine (TMA), 425-426 Trivalent chromium, 395 Type 2 diabetes mellitus (T2DM), 159, 161-163, 163t, 166t-168t, 171f, 171t-172t, 173, 207, 214-215, 390-391, 437-438 complications, 177-178, 211t-213t diagnostic tests, 177 level I evidence, of yoga, 186-196 management, 178 pharmacological treatment, 178-181 prevention, 162-170 risk factors, 165 therapeutic yoga, 196

U

Unhealthy plant-based diet, 430 Unilateral nostril breathing (UNB), 329

V

Valvular heart disease, 17–19 Vascular disease, 173 Vascular endothelial growth factor (VEGF), 320–321 Vascular risk factors, 315, 319 Vasovagal syncope (VVS), 283–284 Vegetables, 394, 412 Vegetarian diets, 408 Ventricular arrhythmias, 41, 286 Ventricular arrhythmias, 41, 286 Ventricular musculature, 3 Veterans Affairs–Million Veteran Program, 430 Vipassana meditation, 327 Vipassana meditators, 327–328

W

Waist circumference (WC), 217 Waist-to-hip ratio (WHR), 217 Wechsler Adult Intelligent Scale, 330 Whole-systems ayurvedic medicine, 235

Y

Yama, 262-263 Years of healthy life lost due to disability (YLDs), 403 Years of life lost (YLL), 27 Yoga, 30-31, 114, 148, 258-261, 280-284, 286, 342-344, 357-358, 373-381, 395-396 alcohol-use disorders, 485 antihypertensive therapy, 136-138, 140 asanas, 263 atrial fibrillation (AF), 298-300 based post cardiac surgery protocol, 457 - 458behavioral aspects, of eating, 398-399 cardiac rehabilitation research, 442-445 cardiovascular disease, 358-361, 467 cardiovascular system, 115 changes, in mental health, 319-325

cocaine-use disorders, 486 cognition, 330 coronary heart disease (CHD), 105 CVD risk score management, 104 cytokines, 321-322 dementia development, 330 depression, 358-361 diabetes mellitus, 390-392 eating disorders, 399 elements, 116 functional neuroimaging studies, 79-80 imaging studies, 79 impact, 328-331 management, of HF, 270 mechanisms, 210-214, 312 meditation, 91, 182, 455-456 meta-analysis, 258 metabolic risk factors, 257 mind-body wellness tool, 185-186 nervous system, 482-484 neurobiological measures, 77 neurophysiological level, 482 neuro-transmitters, 322 nicotine-use disorders, 484-485 opioids-use disorders, 485-486 oxidative stress, 320 pain management, 466 physiological effects, 493-494, 494t practice, 202, 315 primary prevention, 495-496 protocols, 117t recommendations, 173 risk factors, for cerebrovascular disease, 330 - 331role addiction, 481-482 T2DM prevention, 165-170 secondary prevention, 496-501 secondary prevention of CAD, 122 meta-analysis, 120 nonrandomized studies, 115 randomized controlled trials, 115-120 stress, 81 stroke, 312 prevention, 315 rehabilitation, 312-315 structural/morphological neuroimaging studies, 79 systematic review, 258 therapeutic effects, 141t-142t therapy, 40, 362 treat fatigue, 467 trials, 151-152 Yoga-based cardiac rehabilitation, 13, 445, 469f Yoga-based intervention (YLP), 170 Yoga-based lifestyle, 208 intervention, 102-104, 242 Yoga-based lifestyle modification program (YLSP), 457 Yoga-based programs, 31-32, 32t Yoga breathing (YB), 322 Yoga-CaRe trials, 32-33, 442 Yoga effect, on genes, 47

Yoga effect, on genes (*Continued*) adversity during stress, 48–49 cellular metabolism, with yoga, 49–52 neuroendocrine mechanism, 47–48 potential pathways connecting yoga, 52–54 Yoga group (YG), 376 Yoga mechanism, 37 arrhythmias, 40–43 cardiac conditions, 37 heart failure, 40 hypertension, 39 ischemic heart disease, 37–39 YOGA My Heart study, 235 Yoga treatment (YT), 270 Yogic approach to prevention, 261–262 Yogic cognitive-behavioral practices, 147–148 Yogic diet, 262 Yogic Management of Hypertension Protocol, 140 Yogic sattvic diet, 418

YOGA FOR CARDIOVASCULAR DISEASE AND REHABILITATION

Integrating Complementary Medicine into Cardiovascular Medicine

Indranill Basu-Ray

Yoga in Cardiovascular Disease and Rehabilitation highlights the recent research, clinical trials, and experiments on yoga and meditation as a preventative and therapeutic measure against various major cardiovascular diseases, including hypertension, hyperlipidemia, coronary artery disease, stroke, vascular dementia, and metabolic syndromes, including Diabetes Mellitus.

Cardiovascular Disease remains the largest killer on the planet. It continues to show an alarming increasing trend in most economies. Chapters discuss yoga's role in ameliorating cardiac dysfunction and the current knowledge about the effects of yoga on the brain, emotion, and vascular factors that initiate and perpetuate vascular inflammation, leading to cardiovascular mortality and morbidity. Cellular, genetic, and molecular effects of yoga based on experimental evidence are also covered in detail, providing readers with the latest research on the effects of yoga and meditation on heart diseases. The mechanism of yoga's action on the autonomic nervous system has been elucidated, explaining its role in many cardiovascular conditions, including heart failure and arrhythmias.


This book also explores current knowledge gaps in yoga research to facilitate further research and is a comprehensive reference to scientists and clinicians who are interested in yoga's health effects, including preventing and treating diseases.

It is a must-read for clinicians from those in family practice to cardiologists as most likely their patients and/or their kin either know or practice yoga, given the over 300 million yoga practitioners worldwide. It is certainly an affordable alternative in many situations, given the accelerating cost of modern medicine.

Key Features

- Highlights all the important historical and current research, clinical trials, and experiments on yoga and meditation- as a preventative and therapeutic entity against various cardiovascular problems
- Covers all major heart diseases, including hypertension, hyperlipidemia, coronary artery disease, heart failure, stroke, . diabetes mellitus, arrhythmias, and more
- Concepts with extensive illustrations and references for better understanding and clinical and research implementation .
- Extensively illustrated with figures, tables, and clinical pathways to elucidate yoga's application in daily clinical practice
- Details yogic postures used in clinical trials to be used for prescribing yoga in different cardiovascular diseases .





ISBN 978-0-323-99645-7

An imprint of Elsevier elsevier.com/books-and-journals